JPH0510074B2 - - Google Patents
Info
- Publication number
- JPH0510074B2 JPH0510074B2 JP61289953A JP28995386A JPH0510074B2 JP H0510074 B2 JPH0510074 B2 JP H0510074B2 JP 61289953 A JP61289953 A JP 61289953A JP 28995386 A JP28995386 A JP 28995386A JP H0510074 B2 JPH0510074 B2 JP H0510074B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- medium
- culture
- iron complex
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002609 medium Substances 0.000 claims description 44
- 150000004698 iron complex Chemical class 0.000 claims description 14
- -1 ethylenediamine di(o-hydroxyphenylacetic acid) iron Chemical compound 0.000 claims description 5
- LMSDCGXQALIMLM-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;iron Chemical group [Fe].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O LMSDCGXQALIMLM-UHFFFAOYSA-N 0.000 claims description 4
- 239000006143 cell culture medium Substances 0.000 claims description 4
- VVDBZDRIMIXITI-UHFFFAOYSA-N 2-[bis(carboxymethyl)amino]acetic acid;iron Chemical compound [Fe].OC(=O)CN(CC(O)=O)CC(O)=O VVDBZDRIMIXITI-UHFFFAOYSA-N 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 60
- 230000000694 effects Effects 0.000 description 20
- 235000004252 protein component Nutrition 0.000 description 18
- 230000004663 cell proliferation Effects 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- JVXHQHGWBAHSSF-UHFFFAOYSA-L 2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydron;iron(2+) Chemical compound [H+].[H+].[Fe+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JVXHQHGWBAHSSF-UHFFFAOYSA-L 0.000 description 13
- 102000004338 Transferrin Human genes 0.000 description 13
- 108090000901 Transferrin Proteins 0.000 description 13
- 239000012581 transferrin Substances 0.000 description 13
- 238000004113 cell culture Methods 0.000 description 11
- 239000004017 serum-free culture medium Substances 0.000 description 11
- 239000000306 component Substances 0.000 description 8
- 150000002505 iron Chemical class 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 238000012258 culturing Methods 0.000 description 7
- 210000004102 animal cell Anatomy 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000007640 basal medium Substances 0.000 description 5
- 238000012136 culture method Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- 238000004114 suspension culture Methods 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000012533 medium component Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004115 adherent culture Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 206010022498 insulinoma Diseases 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 description 2
- 229940082569 selenite Drugs 0.000 description 2
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- AVPCPPOOQICIRJ-UHFFFAOYSA-L sodium glycerol 2-phosphate Chemical compound [Na+].[Na+].OCC(CO)OP([O-])([O-])=O AVPCPPOOQICIRJ-UHFFFAOYSA-L 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61289953A JPS63141584A (ja) | 1986-12-04 | 1986-12-04 | 細胞培養用培地 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61289953A JPS63141584A (ja) | 1986-12-04 | 1986-12-04 | 細胞培養用培地 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63141584A JPS63141584A (ja) | 1988-06-14 |
| JPH0510074B2 true JPH0510074B2 (zh) | 1993-02-08 |
Family
ID=17749871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61289953A Granted JPS63141584A (ja) | 1986-12-04 | 1986-12-04 | 細胞培養用培地 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63141584A (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1307486C (en) * | 1987-10-29 | 1992-09-15 | Michael T. Largen | Hybridoma production |
| JP2507882B2 (ja) * | 1988-02-17 | 1996-06-19 | 工業技術院長 | 外部増殖因子非依存性増殖良好細胞株の製造法 |
| US5378612A (en) * | 1990-05-11 | 1995-01-03 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Culture medium for production of recombinant protein |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS637780A (ja) * | 1986-06-28 | 1988-01-13 | Nippon Zenyaku Kogyo Kk | 細胞への鉄供給方法 |
-
1986
- 1986-12-04 JP JP61289953A patent/JPS63141584A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS637780A (ja) * | 1986-06-28 | 1988-01-13 | Nippon Zenyaku Kogyo Kk | 細胞への鉄供給方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS63141584A (ja) | 1988-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5441288B2 (ja) | 細胞の無タンパク質かつ無血清の培養のための培地 | |
| Brady et al. | Composition and synthesis of gangliosides in rat hepatocyte and hepatoma cell lines | |
| AU4716493A (en) | Animal cell culture | |
| US5573937A (en) | Serum free culture medium | |
| US4757018A (en) | Myeloma cell lines and uses thereof | |
| EP0248656B1 (en) | Composition for cell cultivation and use thereof | |
| JPH0510074B2 (zh) | ||
| WO1993000423A1 (en) | Iron chelate culture medium additive | |
| JP2001120262A (ja) | 生理活性物質の産生増強方法 | |
| CA1340698C (en) | Preparation and uses of interferon-gamma | |
| JP2015027265A (ja) | 細胞培養用培地 | |
| JPH03254679A (ja) | 新規細胞株 | |
| WO1991018925A1 (fr) | Nouveau facteur de stimulation de colonies megacaryocytaires et production de ce facteur | |
| EP0432952A1 (en) | Serum-free culture medium | |
| WO1998000521A1 (fr) | Milieux exempts de serum, methode de culture de cellules d'origine animale, et procede de production de substances physiologiquement actives | |
| JPS62278979A (ja) | 動物細胞の培養方法 | |
| JP2897043B2 (ja) | 完全合成培地 | |
| JP2500384B2 (ja) | 生理活性物質の製造法 | |
| Osaki et al. | Immunocytochemical study of collagen in epidermal growth factor (EGF)-treated osteoblastic cells. | |
| KR20230082372A (ko) | 무단백질 세포 배양 배지 조성물 및 이의 용도 | |
| JPH02222696A (ja) | 蛋白質の産生方法 | |
| JPH0732705B2 (ja) | 動物細胞増殖用組成物およびそれを用いる動物細胞の増殖方法 | |
| JPH02200177A (ja) | 動物細胞培養用組成物、培養方法および生理活性物質の製造法 | |
| JPS6326988B2 (zh) | ||
| JP2001029066A (ja) | ヒト・動物細胞培養液 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |